Immuneering
Cambridge, Massachusetts, United States · Biotechnology, Health Care, Medical · 50 employees
Immuneering is a clinical-stage oncology company focused on keeping cancer patients alive. The Company is developing an entirely new category of cancer medicines, Deep Cyclic Inhibitors. Immuneering’s lead product candidate, atebimetinib (IMM-1-104), is an oral, once-daily Deep Cyclic Inhibitor of MEK designed to improve durability and tolerability, and expand indications to include MAPK pathway-d
Funding history
- Funding Round — $25.0M — Sep 2025
- Funding Round — $37.2M — Jan 2021
- Funding Round — $20.0M — Jan 2020
- Funding Round — $20.0M — Oct 2019
Recent signals
- Sep 09, 2025: Raised $25.0M
- Mar 20, 2025: Igor Matushansky, MD, PhD, Joins Immuneering as Chief Medical Officer
- Jan 05, 2021: Raised $37.2M
- Jan 27, 2020: Raised $20.0M
- Oct 04, 2019: Raised $20.0M
See plans & pricing → Track Immuneering’s funding, hiring, and signals — with verified contacts — on Fundz.